You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧翔藥業(603229.SZ):子公司日前已就阿茲夫定片的加工生產與真實生物簽訂委託加工生產框架協議等等
格隆匯 05-10 19:07

格隆匯5月10日丨奧翔藥業(603229.SZ)發佈股票交易異常波動公吿,公司近日關注到媒體報道將公司列為新冠概念股,經核查,公司全資子公司浙江麒正藥業有限公司(“麒正藥業”)日前已就阿茲夫定片的加工生產與河南真實生物科技有限公司(“真實生物”)簽訂了《委託加工生產框架協議》和《藥品委託生產質量協議》,上述協議為雙方開展合作的框架性文件,不具有約束力,不涉及具體交易金額,未達到信息披露標準。

上述協議涉及的阿茲夫定產品,其上市許可持有人為真實生物,麒正藥業不享有其所有權,僅為受託加工生產企業,具體訂單計劃、結算方式、交貨期限等需等到阿茲夫定獲得批准後,再另行簽署相應合同,雙方能否最終簽署相應合同以及簽署的時間均存在不確定性。麒正藥業相關片劑生產線尚須通過GMP符合性檢查、取得藥品生產許可證C證後,方可進行上市藥品委託生產。

阿茲夫定於2021年獲得國家藥監局批准用於HIV的治療,目前新增臨牀試驗為抗新型冠狀病毒適應症,新增適應症臨牀試驗結果尚未公開發布,且尚未獲得國家藥監局批准。此次合作可能受到宏觀經濟環境、行業政策、市場環境、管理運營等因素影響,合作未來所產生的效益存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account